Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.001
Neutral
RSI(14)
40.135
Neutral
STOCH(KDJ)(9,3,3)
24.229
Neutral
ATR(14)
0.072
Low Volatility
CCI(14)
-46.401
Neutral
Williams %R
65.450
Sell
TRIX(12,20)
-0.507
Sell
StochRSI(14)
91.470
Buy
Search
BioNexus Gene Lab Corp
BGLCAdd to Watchlist
2.019USD
+0.020+1.01%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
4.88MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of BioNexus Gene Lab Corp
Currency: USD Updated: 2026-05-15Key Insights
BioNexus Gene Lab Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 204 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
BioNexus Gene Lab Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
BioNexus Gene Lab Corp Highlights
StrengthsRisks
BioNexus Gene Lab Corp. is a biotechnology company specializing in precision diagnostics and specialty chemical solutions. The Company, through its wholly owned subsidiary Chemrex Corporation Sdn. Bhd., focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its segments include Trading of industrial chemicals, Provision for genomic screening services, and Investment holding. The Provision for genomic screening services segment includes commercializing proprietary blood-based diagnostic test for early disease detection. Its subsidiary MRNA Scientific Sdn. Bhd owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which it uses in its business.
Growing
The company is in a growing phase, with the latest annual income totaling USD 7.42M.
Overvalued
The company’s latest PE is -1.26, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 50.43K shares, increasing 16.55% quarter-over-quarter.
Analyst Rating
Based on
0
analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of BioNexus Gene Lab Corp is 8.44, ranking 36 out of 382 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 22.84K, representing a year-over-year decrease of 98.93%, while its net profit experienced a year-over-year decrease of 12.79%.
Score
Financials
8.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.69
Operational Efficiency
10.00
Growth Potential
8.17
Shareholder Returns
7.34
BioNexus Gene Lab Corp's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of BioNexus Gene Lab Corp is 8.82, ranking 15 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.26, which is -2.18% below the recent high of -1.23 and -12084.32% above the recent low of -153.03.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 204/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15No earnings forecast score is currently available for BioNexus Gene Lab Corp. The Biotechnology & Medical Research industry's average is 8.13.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
No Data
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of BioNexus Gene Lab Corp is 2.75, ranking 370 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.23 and the support level at 1.88, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
2.010
Buy
MA10
2.027
Sell
MA20
2.101
Sell
MA50
2.235
Sell
MA100
2.634
Sell
MA200
3.884
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of BioNexus Gene Lab Corp is 2.70, ranking 200 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 2.16. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
2.15
VaR
--
240-Day Maximum Drawdown
+82.59%
240-Day Volatility
+186.13%
Return
Best Daily Return
60 days
+12.89%
120 days
+12.89%
5 years
--
Worst Daily Return
60 days
-8.80%
120 days
-15.32%
5 years
--
Sharpe Ratio
60 days
-0.54
120 days
-2.38
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+82.59%
3 years
--
5 years
--
Return-to-Drawdown Ratio
240 days
-0.55
3 years
--
5 years
--
Skewness
240 days
+11.79
3 years
+9.74
5 years
--
Volatility
Realised Volatility
240 days
+186.13%
5 years
--
Standardised True Range
240 days
+19.21%
5 years
--
Downside Risk-Adjusted Return
120 days
-326.53%
240 days
-326.53%
Maximum Daily Upside Volatility
60 days
+62.55%
Maximum Daily Downside Volatility
60 days
+50.97%
Liquidity
Average Turnover Rate
60 days
+0.30%
120 days
+2.57%
5 years
--
Turnover Deviation
20 days
-99.65%
60 days
-99.57%
120 days
-96.39%
Peer Comparison
Biotechnology & Medical Research
BioNexus Gene Lab Corp
BGLC
4.55 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
